Afya Limited Releases 2024 Sustainability Report
The document, which presents Afya's trajectory throughout 2024, follows the Global Reporting Initiative (GRI) standards and is aligned with the Sustainable Development Goals (SDGs). It also reports specific indicators from the Sustainability Accounting Standards Board (SASB) and elements of the International Integrated Reporting Council (IIRC). The sustainability report contains some of the results of the fifth Greenhouse Gas (GHG) Emissions Inventory. Both of which have undergone individual audits by KPMG. The report is divided into two publications a narrative document and a technical annex in Excel format, which addresses all GRI and SASB indicators.
Afya's 2024 Sustainability Report is available at: https://ir.afya.com.br/annual-report/
About Afya Limited (Nasdaq: AFYA, B3: A2FY34)
Afya is a leading medical education group in Brazil based on the number of medical school seats, delivering an end-to-end physician-centric ecosystem that serves and empowers students and physicians to transform their ambitions into rewarding lifelong experiences from the moment they join us as medical students through their medical residency preparation, graduation program, continuing medical education activities and offering medical practice solutions to help doctors enhance their healthcare services through their whole career.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250721441017/en/
Contacts
Investor Relations Contact:Afya Limitedir@afya.com.br
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
7 hours ago
- Associated Press
Dr. Ian Weisberg Launches National Scholarship to Support Undergraduate Medical Students with a Vision for Advancing Healthcare
Niceville, Florida--(Newsfile Corp. - August 3, 2025) - The Dr. Ian Weisberg Scholarship for Medical Students has officially opened applications for its 2025 award cycle, offering a unique opportunity for undergraduate students across the United States who are pursuing a future in medicine. Created by esteemed cardiac electrophysiologist Dr. Ian Weisberg, the scholarship is designed to support students demonstrating academic excellence and a compelling commitment to shaping the future of healthcare through innovation, compassion, and clinical leadership. [ This image cannot be displayed. Please visit the source: ] To view an enhanced version of this graphic, please visit: Open to undergraduate students enrolled in accredited colleges or universities, the scholarship invites applicants to submit a thoughtful and original essay addressing the following prompt: 'Medicine is not just about treating illness-it is about understanding the human condition and making a meaningful impact on people's lives. How do you envision yourself contributing to the future of healthcare? What drives your passion for medicine, and how do you plan to make a difference in the lives of your patients and the world?' Essays should be between 800 and 1,200 words and will be evaluated on originality, clarity, passion, and alignment with the values of the scholarship. The deadline for submissions is October 15, 2025, and the selected recipient will be announced on November 15, 2025. Dr. Ian Weisberg -a highly respected figure in the medical field-brings decades of clinical expertise and a lifelong commitment to patient care, procedural advancement, and medical mentorship. Through this scholarship initiative, Dr. Ian Weisberg is further extending his mission of supporting the next generation of healthcare leaders. He has held pivotal roles at institutions such as the Okaloosa Heart and Vascular Center and the Heart Rhythm Center in Florida, where his work has contributed to life-saving procedures including atrial fibrillation ablations and the implantation of cardiac devices. While the Dr. Ian Weisberg Scholarship for Medical Students bears his name, the focus of the program lies firmly on the future-on nurturing students with the vision, empathy, and dedication required to meet tomorrow's medical challenges. Dr. Ian Weisberg has continually advocated for education and access in medicine, believing firmly that talent and passion should never be hindered by financial constraints. As part of his broader philanthropic efforts, Dr. Ian Weisberg has also worked internationally, notably contributing to the design and planning of electrophysiology infrastructure at Tenwek Hospital in Kenya. These experiences continue to shape his belief in equipping young medical professionals with the tools to create a global impact. This scholarship is not bound by geography-students from any region in the United States are encouraged to apply. The program's national reach ensures that diverse voices and perspectives from across the country are represented. Applicants are encouraged to visit the official scholarship website at for full eligibility details and essay submission guidelines. Contact Information: Spokesperson: Dr. Ian Weisberg Organization: Dr. Ian Weisberg Scholarship for Medical Students Website: Email: [email protected] To view the source version of this press release, please visit
New York Times
9 hours ago
- New York Times
A Cancer Patient Chose Assisted Death. That Wasn't the Last Hard Choice.
The crowd was expectant when Tatiana Andia took the microphone: She was a hero to many in the room, the woman who negotiated cheaper drug prices for Colombia. But that day, at a conference for policymakers and academics on the right to health in Latin America, there was a more intimate topic she wanted to discuss. 'A year ago I was diagnosed with a terminal lung cancer,' she began, 'one that's incurable, catastrophic, all the terrible adjectives.' She gave a small laugh, acknowledging the whole thing sounded preposterous. The air in the packed conference room went still. Ms. Andia, 44, a professor and a former official in Colombia's health ministry, said she was going to speak not as an expert, but from a different perspective, one newly acquired — that of a patient. A particular health rights issue preoccupied her these days, she said: the right to death. No one, she went on, wants to talk to me about dying. She began to speak faster and faster, and her hands fluttered around her face like small birds. People in the audience looked at the floor, the ceiling, their laps. 'How come we can't talk about having a dignified death when we talk about the right to health?' she demanded. Want all of The Times? Subscribe.
Yahoo
20 hours ago
- Yahoo
Meet The Biotech Startup Challenging Ozempic With A Fat-Burning Pill That Lets You Keep Eating
Imagine shedding weight while sitting quietly watching TV, even without cutting calories. A pioneering pill called SANA, created by Uruguayan startup Eolo Pharma, could one day make that possible. Early human data in a statement by Eolo Pharma shows it can burn fat even at rest, without appetite suppression or serious side effects. That breakthrough could reshape global obesity treatment. Biotech Startup Pioneers First-in-Class Therapies to Treat Obesity and Metabolic Disease Eolo Pharma is a clinical-stage biotechnology company focused on pioneering therapies for obesity and metabolic diseases. The company says it develops first-in-class small-molecule drugs that activate the body's own energy-burning pathways rather than relying on appetite suppression. Its lead candidate, SANA, is the first compound shown to safely activate creatine-dependent thermogenesis in humans, offering a novel approach to resetting metabolic health. Don't Miss: Accredited Investors: Grab Pre-IPO Shares of the AI Company Powering Hasbro, Sephora & MGM— 'Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can Headquartered in Delaware with strong scientific roots in South America, Eolo Pharma is a spin-off of the Institut Pasteur de Montevideo, a non-profit foundation that promotes scientific and technological research. The company says it is backed by more than a decade of research into metabolic disorders and cardiometabolic complications. Eolo Pharma's proprietary library of 60 novel chemical entities includes molecules designed to address high-burden, non-communicable diseases such as obesity, type 2 diabetes, non-alcoholic steatohepatitis, hypertension, amyotrophic lateral sclerosis, and Alzheimer's disease. Eolo Pharma's leadership team includes CEO María Pía Garat, a biotech industry leader with a postgraduate degree from Instituto de Empresa Business School; co-founder and Chief Scientific Officer Carlos Escande, a former Mayo Clinic investigator specializing in cardiometabolic disorders; Chief Chemistry Officer Virginia Lopez, a chemist from Uruguay; and Chief Medical Officer Carlos Batthyany, who also serves as head of the Institut Pasteur de Montevideo. Trending: $100k+ in investable assets? – no cost, no obligation. How SANA Activates Fat Burning Without Appetite Suppression SANA is a salicylate‑based nitroalkene compound originally developed to target inflammation, Eolo Pharma says. It was repurposed after researchers discovered it stimulates creatine‑dependent thermogenesis in white and brown fat cells. Unlike glucagon-like peptide‑1 drugs like Ozempic, which reduce hunger, SANA boosts energy expenditure in fat tissue by turning on heat‑producing metabolic pathways at cellular level. According to Eolo Pharma, SANA protected lean mass and reduced fat more than standard salicylate or metformin in preclinical models. "This is the first time a drug has been shown to pharmacologically activate creatine-based thermogenesis, which could lead to a novel therapeutic approach for obesity in humans," Escande said in the statement. "It opens up an entirely new therapeutic pathway for obesity and metabolic disorders."Weight Loss, Glucose Benefits, and Safety Signals In a randomized, double‑blind, placebo‑controlled Phase 1a/b clinical trial, participants received single ascending doses or multiple ascending doses of SANA for 15 days. The trial included 17 healthy lean volunteers and 24 individuals with obesity. According to Eolo Pharma, patients receiving SANA experienced a statistically significant reduction in body weight compared to placebo, along with improvements in fasting glucose and insulin resistance as measured by Homeostatic Model Assessment of Insulin Resistance. No serious adverse events occurred, and only mild headaches and soft stools were reported in some subjects. A Nature Metabolism study published in June describes SANA as a first‑in‑class small molecule that activates creatine‑dependent thermogenesis in preclinical models and shows safety and early metabolic benefits in a phase 1A/B trial in humans. The authors suggest SANA as a promising therapeutic candidate for obesity, though they note that its efficacy in humans requires further confirmation in larger trials. Read Next: The average American couple has saved this much money for retirement —? Image: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? APPLE (AAPL): Free Stock Analysis Report TESLA (TSLA): Free Stock Analysis Report This article Meet The Biotech Startup Challenging Ozempic With A Fat-Burning Pill That Lets You Keep Eating originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
